Your browser doesn't support javascript.
loading
Evaluating the Outcome and Patient Safety of Methotrexate, Doxorubicin, and Cisplatin Regimen for Chemotherapy in Osteosarcoma: A Meta-Analysis.
Ismail, Mohamad Dimas; Wiratnaya, I Gede Eka; Raditya, Risang Haryo.
Affiliation
  • Ismail MD; Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.
  • Wiratnaya IGE; Department of Orthopaedic and Traumatology, Faculty of Medicine, Udayana University, Denpasar, Indonesia.
  • Raditya RH; Faculty of Medicine, Maranatha Christian University, Bandung, Indonesia.
Asian Pac J Cancer Prev ; 25(5): 1497-1505, 2024 May 01.
Article in En | MEDLINE | ID: mdl-38809621
ABSTRACT

BACKGROUND:

Several studies of multi-drug regimens for osteosarcoma have shown different efficacies and are still controversial. Meanwhile, chemotherapy options have remained largely unchanged over a couple of decades. This study is designed to ascertain the outcome and safety of Methotrexate, Doxorubicin, and Cisplatin regimen for chemotherapy in osteosarcoma patients through the utilization of meta-analysis.

METHODS:

We interrogated trials that compared the MAP regimen with other regimens as chemotherapy for osteosarcoma from several databases encompassing PubMed, Science Direct, and grey literature (Google Scholar) until December 2022. The analyzed outcomes including Event-Free Survival (EFS), Overall Survival (OS), Tumor Necrosis (TN) rate, and Adverse Event (AE) were then analyzed using RevMan 5.4 software in fixed or random effect models.

RESULTS:

Our meta-analysis comprised 8 prospective articles that evaluated a cumulative number of 2920 OS patients. The analysis results indicated no meaningful difference in 5-year EFS (OR=0.99, 95% CI=0.77-1.27, [P = 0.91]) and neoadjuvant chemotherapy response (TN) (OR=0.76, 95% CI=0.49-1.17, [P = 0.22]) between the MAP and control groups. Furthermore, 5-year OS analysis revealed a significant association in the control group (OR=0.82, 95% CI=0.68-0.99, [P = 0.04]). However, the control group was associated with statistically meaningful AE compared to the MAP group, particularly in thrombocytopenia (OR=0.46, 95% CI=0.23-0.90, [P = 0.02]) and fever (OR=0.34, 95% CI=0.26-0.46, [P < 0.00001]).

CONCLUSION:

The present meta-analysis showed that the MAP regimen remains preferable in treating osteosarcoma patients despite no significant outcome compared to the other regimens considering the less frequent AE in the MAP regimen.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Doxorubicin / Osteosarcoma / Methotrexate / Cisplatin Limits: Humans Language: En Journal: Asian Pac J Cancer Prev / Asian pac. j. cancer prev / Asian pacific journal of cancer prevention Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Doxorubicin / Osteosarcoma / Methotrexate / Cisplatin Limits: Humans Language: En Journal: Asian Pac J Cancer Prev / Asian pac. j. cancer prev / Asian pacific journal of cancer prevention Journal subject: NEOPLASIAS Year: 2024 Document type: Article Affiliation country: Country of publication: